Clinical Trial Update: RAD001 and Erlotinib in Patients With Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial investigating RAD001 ( everolimus ) and erlotinib in patients with neuroendocrine tumors; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• ERLOTINIB (Erlotinib)
• RAD001 (everolimus)

Snippet

Sponsor: University of California, San Francisco | Conditions: Neuroendocrine Tumors | Phase 2 | Status: TERMINATED | Results posted: 2020-09-29